Browsing Radiotherapy and Imaging by author "Haviland, Joanne"
Now showing items 1-13 of 13
-
A multicentre study of the evidence for customized margins in photon breast boost radiotherapy.
Harris, EJ; Mukesh, MB; Donovan, EM; Kirby, AM; Haviland, JS; et al. (BRITISH INST RADIOLOGY, 2016-01-01)OBJECTIVE: To determine if subsets of patients may benefit from smaller or larger margins when using laser setup and bony anatomy verification of breast tumour bed (TB) boost radiotherapy (RT). METHODS: Verification imaging ... -
Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial.
Bhattacharya, IS; Haviland, JS; Hopwood, P; Coles, CE; Yarnold, JR; et al. (ELSEVIER IRELAND LTD, 2019-05)BACKGROUND: In an era of low local relapse rates after adjuvant breast radiotherapy, risks of late normal-tissue effects (NTE) need to be balanced against risk of relapse. NTE are assessed using patient-reported outcome ... -
Does breast composition influence late adverse effects in breast radiotherapy?
Juneja, P; Bonora, M; Haviland, JS; Harris, E; Evans, P; et al. (CHURCHILL LIVINGSTONE, 2016-04-01)BACKGROUND: Large breast size is associated with increased risk of late adverse effects after surgery and radiotherapy for early breast cancer. It is hypothesised that effects of radiotherapy on adipose tissue are responsible ... -
Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation.
Brunt, AM; Haviland, JS; Kirby, AM; Somaiah, N; Wheatley, DA; et al. (ELSEVIER SCIENCE LONDON, 2021-06-10)INTRODUCTION: The phase 3 FAST-Forward trial reported outcomes for 26 and 27 Gy schedules delivered in 5 fractions over 1 week versus 40 Gy in 15 fractions over 3 weeks in 4000 patients. We discuss concerns raised by the ... -
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
Haviland, J; Sydenham, M; Hopwood, P; Kirby, A; Somaiah, N; et al. -
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
Murray Brunt, A; Haviland, JS; Wheatley, DA; Sydenham, MA; Alhasso, A; et al. (ELSEVIER SCIENCE INC, 2020-05-23)BACKGROUND: We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international standard ... -
Internal mammary node irradiation in breast cancer: does benefit outweigh risk?
Coles, CE; Haviland, JS; Kirby, AM (ELSEVIER SCIENCE INC, 2020-12-01) -
Is breast seroma after tumour resection associated with patient-reported breast appearance change following radiotherapy? Results from the IMPORT HIGH (CRUK/06/003) trial.
Bhattacharya, IS; Haviland, JS; Perotti, C; Eaton, D; Gulliford, S; et al. (ELSEVIER IRELAND LTD, 2019-07)BACKGROUND: Seroma describes a collection of serous fluid within a cavity, occurring following surgery. Seroma is associated with normal tissue effects (NTE) following breast radiotherapy, as reported by clinicians and on ... -
Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer.
Wilkins, AC; Gusterson, B; Szijgyarto, Z; Haviland, J; Griffin, C; et al. (ELSEVIER SCIENCE INC, 2018-06-01)PURPOSE: To assess whether the cellular proliferation marker Ki67 provides prognostic information and predicts response to radiation therapy fractionation in patients with localized prostate tumors participating in a ... -
Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
Coles, CE; Griffin, CL; Kirby, AM; Titley, J; Agrawal, RK; et al. (ELSEVIER SCIENCE INC, 2017-09-09)BACKGROUND: Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced by patient age and clinicopathological factors. We hypothesise that ... -
Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial.
Bhattacharya, IS; Haviland, JS; Kirby, AM; Kirwan, CC; Hopwood, P; et al. (2019-02)Purpose IMPORT LOW demonstrated noninferiority of partial-breast and reduced-dose radiotherapy versus whole-breast radiotherapy for local relapse and similar or reduced toxicity at 5 years. Comprehensive patient-reported ... -
Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial.
Bhattacharya, IS; Haviland, JS; Kirby, AM; Kirwan, CC; Hopwood, P; et al. (AMER SOC CLINICAL ONCOLOGY, 2019-02-01)PURPOSE: IMPORT LOW demonstrated noninferiority of partial-breast and reduced-dose radiotherapy versus whole-breast radiotherapy for local relapse and similar or reduced toxicity at 5 years. Comprehensive patient-reported ... -
The UK HeartSpare Study (Stage II): Multicentre Evaluation of a Voluntary Breath-hold Technique in Patients Receiving Breast Radiotherapy.
Bartlett, FR; Donovan, EM; McNair, HA; Corsini, LA; Colgan, RM; et al. (ELSEVIER SCIENCE LONDON, 2017-03-01)AIMS: To evaluate the feasibility and heart-sparing ability of the voluntary breath-hold (VBH) technique in a multicentre setting. MATERIALS AND METHODS: Patients were recruited from 10 UK centres. Following surgery for ...